Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557

Advancements in Regenerative Medicine: A Multidisciplinary Review of Innovations and Collaborative Approaches

Saeed Ibrahim Saeed Alwizrah[1], Abrar Abdullah Al bahr[2], JAZZAA OTAYBAN HURAN ALRUWAILI[3], Rehab walan bakkari[4], ABDULRHMAN MUSHBAB OUDAH AL AHMARI[5], naser Ayed naser Alshahrani[6], Alanood ali alwadie[7], SAMI MAHLI HAMED ALSHARARI[8], MOHAMMAD BATAH HADIJ ALRUWAILI[9], Ahood obeed alanzi[10], Alanoud Monzel Alonazi[11], Ameinah Mosem ALmotiri[12], Fadiah Naja Almutiri[13], Hanan Alamlah Khulaif Alshammari[14], Ala'a Hayas Abdullah Alzahrani[15], MOHAMMED HABBAS MATER ALSHAMMARI[16]

Abstract

Advances in regenerative medicine have transformed the ability to repair and restore damaged tissues and organs. The incorporation of artificial intelligence (AI) into this interdisciplinary discipline improves the analysis and use of complicated datasets, allowing for advances in treatment procedures.This review synthesizes the existing research on the use of AI technologies in regenerative medicine, with an emphasis on drug discovery, disease modeling, and customized treatment. A thorough search was undertaken across many databases, including PubMed, Scopus, and Google Scholar, to find relevant papers published up to 2023.The results show that AI technologies, including deep learning and machine learning algorithms, considerably increase drug development efficiency by evaluating massive volumes of molecular data to uncover possible therapeutic options. Furthermore, AI improves illness modeling by allowing the development of patient-specific models that account for unique genetic and environmental variables. Predictive modeling using AI provides insights into therapy reactions, allowing for customized medical methods adapted to particular patient requirements.The use of AI in regenerative medicine offers a great opportunity to advance treatment techniques, improve diagnostic accuracy, and improve patient outcomes. However, issues like as data quality, ethical concerns, and regulatory compliance must be solved before AI can fully fulfill its promise in this industry. Future studies should include longitudinal studies to assess AI's long-term influence on healthcare procedures and patient care.

Keywords: *Regenerative Medicine, Artificial Intelligence, Drug Discovery, Personalized Medicine, And Disease Modeling.*

[1] Ksa, Ministry of Health, Wadi Dawasir General Hospital
[2] Ksa, Ministry of Health, Maternity and Children Hospital Hafar AlBatin.
[3] Ksa, Ministry of Health, Al-Jouf Health Pool.
[4] Ksa, Ministry of Health, Al-Eidabi General Hospital
[5] Ksa, Ministry of Health, Khamis Mushayt General Hospital
[6] Ksa, Ministry of Health, hospital Asser
[7] Ksa, Ministry of Health, Aldiriyah hospital
[8] Ksa, Ministry of Health, Al-Jouf Health Pool
[9] Ksa, Ministry of Health, Al-Jouf Health Pool
[10] Ksa, Ministry of Health, Al Nahda Western Health Center
[11] Ksa, Ministry of Health, Al Nahda Western Health Center
[12] Ksa, Ministry of Health, Al Nahda Western Health Center
[13] Ksa, Ministry of Health, Al Nahda Western Health Center
[14] Ksa, Ministry of Health, King Abdulaziz Specialist Hospital
[15] Ksa, Ministry of Health,
[16] Ministry of Health ,public health ,AJA HOSPITAL

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557

Introduction

Artificial intelligence (AI) means the creation of computer systems capable of doing activities that would normally need human intellect. This encompasses learning, thinking, perception, and problem-solving. AI systems are intended to emulate human cognition and operate independently, learning from information and past experiences to enhance efficiency continuously [1,2]. The notion of artificial intelligence has been known for centuries. Nonetheless, recent advancements in deep learning, machine learning, as well as the processing of natural languages have enabled the development of increasingly advanced AI systems.

Machine learning allows researchers to evaluate massive quantities of data, discover patterns, make forecasts according to the information, and ultimately learn from their errors and alter their behavior appropriately sans being specifically programmed. The processing of natural language, picture recognition, self-driving cars, and medical technology are all examples of applications that employ machine learning [3-9]. Deep learning represents a subfield of learning algorithms that employ machine learning algorithms to derive information from information. These neural systems are intended to imitate the architecture and operations of the brain of humans, enabling them to recognize more complicated patterns and make judgments depending on the data with which they were taught [10,11].

Deep learning has transformed the area of artificial intelligence, allowing robots to execute things that were previously deemed impossible. One of deep learning's primary benefits is its capacity to handle huge and complicated datasets [12]. Conventional artificial intelligence systems struggle to interpret information that is excessively big or complicated for humans to handle. Deep learning algorithms, on the other hand, can process many thousands of records and uncover patterns that a person would be unable to discern [13,14]. Another feature of deep development is its capacity to acquire knowledge and advance with time [15].

Conventional machine learning techniques often lack memory, forcing humans to manually alter their variables and parameters to increase their performance. Some algorithms used for deep learning, including short-term and long-term memory as well as recurrent neural network algorithms, may automatically adapt to the input they are processing [16,17]. This indicates that deep learning techniques will continue to improve and evolve as they handle additional information [18,19]. Regenerative healthcare is an expanding field that uses cutting-edge technologies including stem cell-based treatments, genome editing, and tissue engineering to repair or restore destroyed or damaged organs and tissues [20-22].

Regenerative medicine has the potential to transform medical therapy, providing hope to patients struggling with a variety of illnesses such as coronary artery disease, type 2 diabetes, as well as neurological problems [23,24]. However, generating successful regenerative medicines requires the capacity to evaluate massive volumes of complex information, which is where artificial intelligence gets in. This work makes a unique contribution by consolidating and assessing the current literature on AI applications in regenerative healthcare, offering an overview, highlighting gaps, and suggesting new research areas. By using a comprehensive approach, we analyze not just empirical research, but also theoretical ideas and academic opinions.

Artificial Intelligence for Regenerative Medicine

AI has become an important component in doing computer models and in silico investigations in medical applications, and it has various benefits, including reduced costs and quicker findings when compared to conventional medical inquiry procedures, such as medical as well as laboratory techniques [25, 26, 27]. Several current programs attempt to incorporate AI into a variety of sectors, such as but not restricted to medicine, pharmacology, and healthcare [28,29,30]. These initiatives attempt to use AI to improve and simplify a variety of procedures, including medication discovery, illness detection, and medical treatment. Researchers and practitioners anticipate that incorporating AI will result in more accurate and efficient results, eventually increasing the quality of life for people and communities [30,31].

To be more precise, deep learning may assist speed up the advancement of regenerative medicinal products by making it easier to analyze enormous databases of molecular as well as genetic information to uncover

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557

patterns and connections that human researchers may overlook. This may help researchers comprehend the illness's root causes and design more effective treatments to combat them.

There are an enormous number of compounds in the chemical universe, which presents both potential and obstacles to the development and discovery of medicines. Drug discovery in regenerative medicine is the process of finding chemicals, biological products, or other medicinal products that may stimulate tissue regeneration and restore functionality. The lack of sophisticated technology limits medical development.

Traditional drug development techniques may be time-consuming and costly since they require the production and evaluation of hundreds of chemicals to find prospective therapeutic candidates. Another key challenge in drug development is determining whether putative medication prospects are secure and efficient [32]. To address these issues, AI was developed as a strong tool capable of analyzing enormous databases of chemical substances and predicting which therapies are most effective for certain conditions. Analyzing chemical arrangements and characteristics has enabled the detection of patterns and relationships, which may aid in the identification of prospective medication candidates. This data may be used to select substances for additional development and testing.

AI may also help validate the medication's target, which corresponds to the precise biological substance or pathway with which the medicine is intended to interact. Using AI, researchers may acquire knowledge about the drug target's function and potential efficacy while saving time and costs. Furthermore, it can forecast the toxicity of possible medication candidates by examining their molecular makeup and characteristics. This may aid in detecting possible safety issues prior to the drug development process, lowering the likelihood of adverse events. Furthermore, AI may help to create novel compounds that are suited for certain medicinal purposes. Furthermore, it may aid in the discovery of novel compounds that are more probable to be successful therapies for certain disorders.

While artificial intelligence has an opportunity to greatly improve drug development, researchers and doctors must address obstacles such as data quality, openness, and regulatory compliance. Addressing these problems will allow them to continue refining AI technologies and improving drug development efficiency and efficacy. AI tools are currently being used in multiple facets of the development and discovery of drugs, such as pharmaceutical design (for example, target protein architecture forecasting, drug-protein connections, as well as de novo medication layout) and drug evaluation (such as forecasting physical characteristics, biological activity, as well as toxic effects) [33,34].

Disease modeling entails developing in vitro instances of illnesses that may be used to investigate the underlying causes of the illness and test prospective remedies. Disease modeling allows researchers to get a full knowledge of disease pathophysiology, uncover novel treatment goals, and obtain understanding of regeneration mechanisms that restore normal tissue function. Furthermore, illness modeling may be used to test new medications and select the most promising options for future research [43,44,45]. AI can assist researchers in analyzing data collected by illness models and identifying patterns and connections that could not be instantly obvious. This may assist in identifying novel therapeutic targets and prospective drug candidates for future development.

One of the primary benefits of disease simulation is the capacity to develop customized models of illnesses using patient-specific cells. This enables researchers to examine the illness in a more realistic and relevant context since each model represents the patient's specific genetic and environmental variables that trigger the illness [46,47]. AI may assist uncover indicators, genetic changes, and other variables that contribute to illness genesis and progression. This information may then be used to improve illness models and find new remedies. Additionally, these models may be used to assess the success of customized therapies, including gene- or cell-based treatments, which can be adjusted to each patient's specific requirements. AI systems can discover genetic abnormalities linked to certain illnesses, enabling researchers to create individualized therapies based on an individual's genetic profile. AI may potentially be used in the growth of gene treatments for uncommon genetic illnesses.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557

Predictive modeling entails utilizing information to teach machine/deep learning algorithms to forecast potential results according to unknown facts. Its relationship to regenerative medicine stems from its common objective of enhancing individual healthcare and improving treatment techniques. Predictive modeling is important because it provides insights into a variety of domains, including illness progression prediction, identifying people at risk of acquiring certain disorders and improving treatment regimens.

Predictive analysis is a difficult undertaking in healthcare because of the intricacy of the data and the enormous quantity of data included [48,49]. AI provides high-accuracy prediction models for assessing medical and biological information in order to uncover patterns and relationships that may be utilized to forecast future results. Machine learning techniques can uncover elements that influence illness onset and progression. This data may then be utilized to generate more accurate prediction models for identifying individuals at risk of acquiring certain illnesses and optimizing treatment strategies. Furthermore, AI enables the creation of individualized prediction models by examining patient data, such as genomes, proteomics, and metabolomics. It aids in the identification of individual disease process distinctions, which may then be utilized to generate individualized prediction models. This data is then utilized to create individualized treatment regimens that are suited to each patient's unique requirements. Furthermore, by analyzing biological data, AI can find potential new drug candidates. It may identify targets and pathways associated with certain illnesses, allowing for the creation of medications that target these pathways while also improving the efficacy of current ones.

Personalized Medicine

Personalized medicine seeks to give individualized healthcare services to patients based on biological, environmental, as well as behavioral characteristics. However, forecasting a patient's reaction to a certain therapy remains a considerable difficulty owing to the system's complexity [50,51]. AI can assist address this issue by evaluating patient data and detecting patterns and relationships that might predict treatment results. One method AI may help with tailored treatment is by examining a patient's genetic data. AI algorithms may uncover genetic differences associated with certain illnesses or treatment responses, allowing for the creation of individualized treatment regimens based on the patient's genetic profile. Another method AI may aid is by evaluating patient health data, such as digital medical records, imaging information, and person-reported results. This information may show trends and relationships that help anticipate treatment results and provide personalized treatment approaches. For example, AI algorithms may identify patients who are most likely to profit from a certain medicine or forecast which patients would have unfavorable responses to it. AI may also create individualized treatment regimens based on the patient's choices and values.

Evaluating patient feedback alongside additional data may help find treatment alternatives that are consistent with the patient's values and preferences. AI has an opportunity to greatly improve the efficacy of customized medicine by giving new resources and knowledge to physicians and researchers. However, concerns about data privacy, prejudice, and regulatory constraints must be addressed. By overcoming these obstacles, researchers and physicians may increase AI technology and patient care quality.

Artificial Intelligence in Related Areas of Regenerative Health Care

Immunotherapy is an approach that uses the immune system to selectively target cancerous cells [52]. It entails providing medicines that inhibit or stimulate certain immune cell transmitters or delivering modified immune cells capable of recognizing and attacking cancer cells [53,54]. This method has the potential to provide a long-term anti-tumor response in some cancer patients. Immunotherapy is a fast-changing discipline, with continuing research aimed at finding novel targets and generating more effective treatments to improve outcomes. The effectiveness of present immunologic cancer therapies is based on drugs that stimulate or improve the immune system's response to malignancy. In addition to the effective use of immunological checkpoint inhibitors, neoantigen vaccines, and T-cell transfer, there is potential for additional breakthroughs using novel technologies and methodologies [54].

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557

The basic objective of immune therapy is to tailor therapies to each patient's distinct disease features, particularly the immune system's reaction to tumor cells. Academics are working to uncover predictive biomarkers for therapy response and resistance, as well as to develop treatment models. They investigate the behavior of every cell group involved in order to get a better understanding of the immune system's interactions with malignancies. Researchers may use simulation models using mathematical equations for every cellular subgroup and biochemical mediator throughout immunological encounters to track changes in individual cell groups over time. Furthermore, these mathematical models may help explain how different immune cells react to tumors with varying pathogenicity and proliferation rates [54,55].

With the advent of AI, simulation frameworks have been upgraded to reflect increasingly sophisticated features of the tumor-immune interaction. This involves taking into consideration the geographical patterns of cancers, variability in cytokine action, and other signaling and regulating variables. To effectively simulate immunogenic malignancies, academics must take into account the diverse geographic distributions of tumors as well as immune cell populations. The role of cytokines in mediating tumor-immune interactions complicates these theories further. This may need to include reaction or transport procedures, such as material exchange with the immediate surroundings. Translating immunotherapy principles into clinical practice may be a time-consuming and difficult task. To overcome this, researchers are increasingly turning to artificial intelligence models that can anticipate hypothetical therapeutic results and give knowledge of the basic mechanisms that influence the efficacy or failure of immunotherapies.

Personalized computational models were developed as well to improve the effectiveness of recently emerging immunotherapies in clinical trials and raise the probability of governmental acceptance. However, this individualized method contradicts the conventional paradigm of therapeutic development, which entails applying pre-determined treatment regimens consistently to all patients in trial groups. Implementing tailored models would need a departure from the present clinical trial paradigm. To increase the precision and specificity of clinical practice models, more precise and spatially defined medical information is needed. The accessibility of such information would enable researchers to create more precise models of individual diseases and therapies by adding comprehensive tumor-immune interactions. Collaboration between AI experts and doctors is required to support the production of well-founded clinical studies. This partnership would allow for the quantification of qualitative hypotheses, resulting in dosage customization and optimization, as well as immunotherapeutic protocol scheduling. Such a strategy would speed up the transfer from new ideas to clinical practice, eventually improving medical results for particular patients [54].

Genetic engineering is the technique of modifying an organism's genetic material to change or improve its traits. This technique allows for the precise manipulation of particular genes inside an organism's genome, resulting in desired modifications in features or capabilities. The method may include the addition, deletion, or alteration of genes to obtain the desired results [55,56]. Regenerative medicine relies heavily on genetic engineering. One of the primary uses of genetic modification is to change stem cells to improve their characteristics and control their development into particular cell types, resulting in increased regeneration capacity [56]. Genetic engineering may also be utilized to alter the genetic makeup of cells in the human body in order to improve their therapeutic efficacy [57]. Genetic changes may be used to generate induced pluripotent stem cells (iPSCs) that are mature cells that have been reprogrammed. These cells may subsequently be differentiated into other cell types and employed in biological applications including transplantation and medication testing [58].

Additionally, genetic modification is employed in the creation of gene treatments, which include inserting novel genes into the human body in order to cure or prevent illness. Gene treatments may either replace or repair damaged genes which trigger genetic illnesses, or they may generate new genes that improve the body's inherent regeneration capacity [58,60].

In the field of genetics, AI serves two key functions: discovering dangerous genes and developing effective remedies for genetic illnesses. Analyzing the huge quantity of data present in an individual's DNA is a difficult and time-consuming process for humans. Machines, on the other hand, may be used to execute this analysis in an efficient and exact manner, meeting their main goal of reducing the strain of laborious work. AI algorithms may be used to evaluate the expression of genes in cancerous and typical tissue specimens from a cancer patient, allowing predictions about any altered genes in the patient's DNA. The algorithms would train and generate predictions based on the incidence of gene activity in cancerous and typical samples, including fresh data as needed to improve prediction accuracy. Artificial intelligence is using three-dimensional imagery to discover genetic abnormalities in cancers. Machines can correctly identify the existence of a mutation using deep learning as well as neural networks, allowing clinicians to develop more effective medical regimens for patients without requiring diagnostic samples of tissue or operative procedures. These advances in machine learning possess the possibility to improve illness detection, notably for cancer.

We are approaching a new era in which genome-editing techniques will enable us to deactivate or fix genes that cause illness. This development opens up the prospect of life-saving medicines for those suffering from genetic illnesses [61]. Despite considerable advances in technology like as CRISPR, the danger of mistakes remains substantial, and security must be addressed if gene editing is to progress. Machine learning algorithms may help determine where the mutation should be performed and how to properly repair the DNA strand, reducing the possibility of mistakes during the gene editing procedure. AI is extremely useful in tailored medicine. When contrasted with others, our particular DNA contains a large number of variants, meaning that cancer-causing genes in one person's genome would vary in position and degree from those in other with the same condition. AI can determine what genes have been altered by deleterious mutations, allowing them to be addressed in therapeutic procedures [62].

While AI may minimize technical mistakes in altering genes and increase safety, it also poses significant ethical concerns [63]. Some claim that adopting AI increases the chance of malfunctions and believe the non-human component of AI could prove more detrimental than useful. The incorporation of AI into genetic modification raises worries about uneven access to gene therapy depending on money, as well as the possible abuse of gene editing for non-healthcare objectives like physical improvement. Furthermore, religious and moral concerns must be addressed when considering genome modification as a potential cure for hereditary illnesses. It is vital to remember that the precision and objectivity of machine learning techniques and instruments are determined by the standard of the information provided to them as well as the characteristics of the methods themselves. Despite advances in neural networks, the machine cannot reason for itself and is as accurate as the knowledge it is given [64].

Summary

AI has the potential to transform regenerative medicine by analyzing massive molecular and genomic databases, offering insights that humans would be unable to see. However, considerable technological obstacles must be overcome before these solutions may be broadly implemented. One of the drawbacks is a scarcity of big, high-quality datasets required to train complex machine-learning models, which are challenging to completely capture. Because of our incomplete knowledge of cellular and molecular processes, developing reliable computational models that can mimic and predict cell activity across time has enormous technological obstacles. Validating AI systems and obtaining regulatory clearance need substantial clinical testing, which takes time and money. Addressing concerns about data privacy, security, and prejudice is equally vital. Obtaining professional support for technology promising more effective individualized treatment will need overcoming adoption barriers.

Significant continuing research is required to transform AI's theoretical promise in regenerative medicine into real-world solutions that directly enhance patient outcomes. Researchers, politicians, healthcare providers, and AI developers must collaborate to provide adequate protections, oversight mechanisms, and protocols for using AI in regenerative medicine. As AI technologies advance and more high-quality data becomes accessible, the possibility to refine and customize AI algorithms, particularly for regenerative medicine will grow.

References

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557
Bays, H.E.; Fitch, A.; Cuda, S.; Gonsahn-Bollie, S.; Rickey, E.; Hablutzel, J.; Coy, R.; Censani, M. Artificial intelligence and obesity management: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. Obes. Pillars 2023, 6, 100065.

Nelson, S.D.; Walsh, C.G.; Olsen, C.A.; McLaughlin, A.J.; LeGrand, J.R.; Schutz, N.; Lasko, T.A. Demystifying artificial intelligence in pharmacy. Am. J. Health-Syst. Pharm. 2020, 77, 1556–1570.

Kaul, V.; Enslin, S.; Gross, S.A. History of artificial intelligence in medicine. Gastrointest. Endosc. 2020, 92, 807–812.

Lauriola, I.; Lavelli, A.; Aiolli, F. An introduction to Deep Learning in Natural Language Processing: Models, techniques, and tools. Neurocomputing 2022, 470, 443–456.

Alam, A. Possibilities and apprehensions in the landscape of artificial intelligence in education. In Proceedings of the 2021 International Conference on Computational Intelligence and Computing Applications (ICCICA), Maharashtra, India, 26–27 November 2021; pp. 1–8.

Trappey, A.J.C.; Trappey, C.V.; Wu, J.-L.; Wang, J.W.C. Intelligent compilation of patent summaries using machine learning and natural language processing techniques. Adv. Eng. Inform. 2020, 43, 101027.

Liu, L.; Wang, Y.; Chi, W. Image Recognition Technology Based on Machine Learning. IEEE Access 2020, 1.

Qayyum, A.; Usama, M.; Qadir, J.; Al-Fuqaha, A. Securing Connected & Autonomous Vehicles: Challenges Posed by Adversarial Machine Learning and the Way Forward. IEEE Commun. Surv. Tutor. 2020, 22, 998–1026.

Strzelecki, M.; Badura, P. Machine Learning for Biomedical Application. Appl. Sci. 2022, 12, 2022.

Sakshi; Das, P.; Jain, S.; Sharma, C.; Kukreja, V. Deep Learning: An Application Perspective. In Cyber Intelligence and Information Retrieval; Springer: Singapore, 2022; pp. 323–333.

Asmika, B.; Mounika, G.; Rani, P.S. Deep learning for vision and decision making in self driving cars-challenges with ethical decision making. In Proceedings of the 2021 International Conference on Intelligent Technologies (CONIT), Hubli, India, 25–27 June 2021; pp. 1–5.

Mandalapu, V.; Elluri, L.; Vyas, P.; Roy, N. Crime Prediction Using Machine Learning and Deep Learning: A Systematic Review and Future Directions. IEEE Access 2023, 11, 60153–60170.

Taye, M.M. Understanding of Machine Learning with Deep Learning: Architectures, Workflow, Applications and Future Directions. Computers 2023, 12, 91.

Wan, K.W.; Wong, C.H.; Ip, H.F.; Fan, D.; Yuen, P.L.; Fong, H.Y.; Ying, M. Evaluation of the performance of traditional machine learning algorithms, convolutional neural network and AutoML Vision in ultrasound breast lesions classification: A comparative study. Quant. Imaging Med. Surg. 2021, 11, 1381–1393.

Kaur, G.; Adhikari, N.; Krishnapriya, S.; Wawale, S.G.; Malik, R.Q.; Zamani, A.S.; Perez-Falcon, J.; Osei-Owusu, J. Recent Advancements in Deep Learning Frameworks for Precision Fish Farming Opportunities, Challenges, and Applications. J. Food Qual. 2023, 2023, 4399512.

Graves, A. (Ed.) Long short-term memory. In Supervised Sequence Labelling with Recurrent Neural Networks; Springer: Berlin/Heidelberg, Germany, 2012; pp. 37–45.

Medsker, L.; Jain, L.C. Recurrent Neural Networks: Design and Applications; CRC Press: Boca Raton, FL, USA, 1999.

Hongen, C.; Zhenyuan, L.; Weinan, Z. The comparison of traditional machine learning and deep learning methods for malicious website detection. In Proceedings of the International Conference on Electronic Information Engineering and Computer Technology (EIECT 2021), Chiang Mai, Thailand, 14–15 October 2021; p. 120871G.

Yang, X.; Zhang, S.; Liu, J.; Gao, Q.; Dong, S.; Zhou, C. Deep learning for smart fish farming: Applications, opportunities and challenges. Rev. Aquac. 2021, 13, 66–90.

de Antonio, M.; Timothy, J.W.D.; James Philip, H.; O'Regan, D.P. Artificial intelligence and the cardiologist: What you need to know for 2020. Heart 2020, 106, 399.

Altyar, A.E.; El-Sayed, A.; Abdeen, A.; Piscopo, M.; Mousa, S.A.; Najda, A.; Abdel-Daim, M.M. Future regenerative medicine developments and their therapeutic applications. Biomed. Pharmacother. 2023, 158, 114131.

Nosrati, H.; Aramideh Khouy, R.; Nosrati, A.; Khodaei, M.; Banitalebi-Dehkordi, M.; Ashrafi-Dehkordi, K.; Sanami, S.; Alizadeh, Z. Nanocomposite scaffolds for accelerating chronic wound healing by enhancing angiogenesis. J. Nanobiotechnol. 2021, 19, 1.

Rajabzadeh, N.; Fathi, E.; Farahzadi, R. Stem cell-based regenerative medicine. Stem Cell Investig. 2019, 6, 19.

Zhong, F.; Jiang, Y. Endogenous Pancreatic β Cell Regeneration: A Potential Strategy for the Recovery of β Cell Deficiency in Diabetes. Front. Endocrinol. 2019, 10, 101.

Tauviqirrahman, M.; Ammarullah, M.I.; Jamari, J.; Saputra, E.; Winarni, T.I.; Kurniawan, F.D.; Shiddiq, S.A.; van der Heide, E. Analysis of contact pressure in a 3D model of dual-mobility hip joint prosthesis under a gait cycle. Sci. Rep. 2023, 13, 3564.

Salaha, Z.F.; Ammarullah, M.I.; Abdullah, N.N.; Aziz, A.U.; Gan, H.-S.; Abdullah, A.H.; Abdul Kadir, M.R.; Ramlee, M.H. Biomechanical Effects of the Porous Structure of Gyroid and Voronoi Hip Implants: A Finite Element Analysis Using an Experimentally Validated Model. Materials 2023, 16, 3298.

Ammarullah, M.I.; Hartono, R.; Supriyono, T.; Santoso, G.; Sugiharto, S.; Permana, M.S. Polycrystalline Diamond as a Potential Material for the Hard-on-Hard Bearing of Total Hip Prosthesis: Von Mises Stress Analysis. Biomedicines 2023, 11, 951.

Thakur, A.; Mishra, A.P.; Panda, B.; Rodríguez, D.C.S.; Gaurav, I.; Majhi, B. Application of Artificial Intelligence in Pharmaceutical and Biomedical Studies. Curr. Pharm. Des. 2020, 26, 3569–3578.

Mak, K.-K.; Pichika, M.R. Artificial intelligence in drug development: Present status and future prospects. Drug Discov. Today 2019, 24, 773–780.

Hamet, P.; Tremblay, J. Artificial intelligence in medicine. Metabolism 2017, 69, S36–S40.

Nsugbe, E. An artificial intelligence-based decision support system for early diagnosis of polycystic ovaries syndrome. Healthc. Anal. 2023, 3, 100164.

Kraljevic, S.; Stambrook, P.J.; Pavelic, K. Accelerating drug discovery. EMBO Rep. 2004, 5, 837–842.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557
Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade, R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today 2021, 26, 80–93.
Jiménez-Luna, J.; Grisoni, F.; Weskamp, N.; Schneider, G. Artificial intelligence in drug discovery: Recent advances and future perspectives. Expert Opin. Drug Discov. 2021, 16, 949–959.
Korshunova, M.; Ginsburg, B.; Tropsha, A.; Isayev, O. OpenChem: A Deep Learning Toolkit for Computational Chemistry and Drug Design. J. Chem. Inf. Model. 2021, 61, 7–13.
Dobariya, A.; Vaghela, V. Artificial intelligence in drug discovery and development: Current status and future perspectives. Drug Discov. Today 2023, 26, 80.
Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; et al. AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022, 50, D439–D444.
David, A.; Islam, S.; Tankhilevich, E.; Sternberg, M.J.E. The AlphaFold Database of Protein Structures: A Biologist's Guide. J. Mol. Biol. 2022, 434, 167336.
Gromski, P.S.; Granda, J.M.; Cronin, L. Universal Chemical Synthesis and Discovery with 'The Chemputer'. Trends Chem. 2020, 2, 4–12.
Duvenaud, D.K.; Maclaurin, D.; Iparraguirre, J.; Bombarell, R.; Hirzel, T.; Aspuru-Guzik, A.; Adams, R.P. Convolutional networks on graphs for learning molecular fingerprints. In Proceedings of the Conference on Neural Information Processing Systems, Montreal, QC, Canada, 7–10 December 2015; Volume 28.
Mayr, A.; Klambauer, G.; Unterthiner, T.; Hochreiter, S. DeepTox: Toxicity Prediction using Deep Learning. Front. Environ. Sci. 2016, 3, 80.
Wallach, I.; Dzamba, M.; Heifets, A. AtomNet: A deep convolutional neural network for bioactivity prediction in structure-based drug discovery. arXiv 2015, arXiv:1510.02855.
Kawaguchi, N.; Nakanishi, T. Animal Disease Models and Patient-iPS-Cell-Derived In Vitro Disease Models for Cardiovascular Biology—How Close to Disease? Biology 2023, 12, 468.
Hasan, M.F. Self-Organization in 3D Neuronal Constructs In Vitro; Lehigh University: Bethlehem, PA, USA, 2020.
Chaudhary, S.; Chakraborty, E. Hydrogel based tissue engineering and its future applications in personalized disease modeling and regenerative therapy. Beni-Suef Univ. J. Basic Appl. Sci. 2022, 11, 3.
Nero, C.; Vizzielli, G.; Lorusso, D.; Cesari, E.; Daniele, G.; Loverro, M.; Scambia, G.; Sette, C. Patient-derived organoids and high grade serous ovarian cancer: From disease modeling to personalized medicine. J. Exp. Clin. Cancer Res. 2021, 40, 116.
Vatine, G.D.; Barrile, R.; Workman, M.J.; Sances, S.; Barriga, B.K.; Rahnama, M.; Barthakur, S.; Kasendra, M.; Lucchesi, C.; Kerns, J.; et al. Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease Modeling and Personalized Medicine Applications. Cell Stem Cell 2019, 24, 995–1005.e1006.
Toma, M.; Wei, O.C. Predictive Modeling in Medicine. Encyclopedia 2023, 3, 590–601.
Yang, C.C. Explainable Artificial Intelligence for Predictive Modeling in Healthcare. J. Healthc. Inform. Res. 2022, 6, 228–239.
Mathur, S.; Sutton, J. Personalized medicine could transform healthcare. Biomed. Rep. 2017, 7, 3–5.
Goetz, L.H.; Schork, N.J. Personalized medicine: Motivation, challenges, and progress. Fertil. Steril. 2018, 109, 952–963.
St-Pierre, F.; Bhatia, S.; Chandra, S. Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies. Cancers 2021, 13, 1988.
Till, S.J.; Francis, J.N.; Nouri-Aria, K.; Durham, S.R. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 2004, 113, 1025–1034.
Spear, T.T.; Nagato, K.; Nishimura, M.I. Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunol. Immunother. 2016, 65, 631–649.
Sniecinski, I.; Seghatchian, J. Artificial intelligence: A joint narrative on potential use in pediatric stem and immune cell therapies and regenerative medicine. Transfus. Apher. Sci. 2018, 57, 422–424.
Walker, R.; Enderling, H. From concept to clinic: Mathematically informed immunotherapy. Curr. Probl. Cancer 2016, 40, 68–83.
Khalil, A.M. The genome editing revolution: Review. J. Genet. Eng. Biotechnol. 2020, 18, 68.
Singh, P.; Sharma, D. Playing with Genes: A Pragmatic Approach in Genetic Engineering. In Digital Forensics and Internet of Things; Willey: Hoboken, NJ, USA, 2022; pp. 45–58.
Hassanzadeh, A.; Shamlou, S.; Yousefi, N.; Nikoo, M.; Verdi, J. Genetically-modified Stem Cell in Regenerative Medicine and Cancer Therapy; A New Era. Curr. Gene Ther. 2022, 22, 23–39.
Zhao, C.; Cheng, Y.; Huang, P.; Wang, C.; Wang, W.; Wang, M.; Shan, W.; Deng, H. X-ray-Guided In Situ Genetic Engineering of Macrophages for Sustained Cancer Immunotherapy. Adv. Mater. 2023, 35, 2208059.
Al Abbar, A.; Ngai, S.C.; Nograles, N.; Alhaji, S.Y.; Abdullah, S. Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy. BioRes. Open Access 2020, 9, 121–136.
Kumar, S.R.P.; Markusic, D.M.; Biswas, M.; High, K.A.; Herzog, R.W. Clinical development of gene therapy: Results and lessons from recent successes. Mol. Ther. Methods Clin. Dev. 2016, 3, 16034.
Bansal, A.; Prakash, R.; Agarwal, S.; Advani, U. Gene therapy and its applications. J. Med. Evid. 2023, 4, 46–56.
Doudna, J.A. The promise and challenge of therapeutic genome editing. Nature 2020, 578, 229–236.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14047 – 14055
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6557

التطورات في الطب التجديدي: مراجعة متعددة التخصصات للابتكارات والمناهج التعاونية

الملخص

الخلفية: أحدثت التطورات في الطب التجديدي تحولًا في القدرة على إصلاح واستعادة الأنسجة والأعضاء التالفة. يعزز دمج الذكاء الاصطناعي (AI) في هذا المجال متعدد التخصصات تحليل واستخدام مجموعات البيانات المعقدة، مما يسمح بتحقيق تقدم في إجراءات العلاج .

الطرق: تجمع هذه المراجعة بين الأبحاث الحالية حول استخدام تقنيات الذكاء الاصطناعي في الطب التجديدي، مع التركيز على اكتشاف الأدوية، ونمذجة الأمراض، والعلاج المخصص. تم إجراء بحث شامل عبر العديد من قواعد البيانات، بما في ذلك PubMed و Scopus وGoogle Scholar، للعثور على الأوراق ذات الصلة المنشورة حتى عام 2023

النتائج: تظهر النتائج أن تقنيات الذكاء الاصطناعي، بما في ذلك التعلم العميق وخوارزميات التعلم الآلي، تزيد بشكل كبير من كفاءة تطوير الأدوية من خلال تقييم كميات ضخمة من البيانات الجزيئية للكشف عن الخيارات العلاجية المحتملة. علاوة على ذلك، يحسن الذكاء الاصطناعي نمذجة الأمراض من خلال السماح بتطوير نماذج مخصصة للمرضى تأخذ في الاعتبار العوامل الجينية والبيئية الفريدة. يوفر النمذجة التنبؤية باستخدام الذكاء الاصطناعي رؤى حول ردود العلاج، مما يسمح باتباع أساليب طبية مخصصة تتكيف مع احتياجات المرضى المحددة .

الخلاصة: يقدم استخدام الذكاء الاصطناعي في الطب التجديدي فرصة عظيمة لتحسين تقنيات العلاج، وزيادة دقة التشخيص، وتحسين نتائج المرضى. ومع ذلك، يجب معالجة القضايا المتعلقة بجودة البيانات، والمخاوف الأخلاقية، والامتثال التنظيمي قبل أن يتمكن الذكاء الاصطناعي من تحقيق كامل وعوده في هذا المجال. يجب أن تتضمن الدراسات المستقبلية دراسات طولية لتقييم التأثير طويل الأجل للذكاء الاصطناعي على إجراءات الرعاية الصحية ورعاية المرضى.

الكلمات المفتاحية: الطب التجديدي، الذكاء الاصطناعي، اكتشاف الأدوية، الطب المخصص، ونمذجة الأمراض.